A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).
Status:
Recruiting
Trial end date:
2023-06-16
Target enrollment:
Participant gender:
Summary
JS002 is a recombinant human anti-PCSK9 monoclonal antibody.The study is a multicenter,
randomized, double-blind, placebo-controlled Phase III clinical study in Chinese patients
with heterozygous familial hypercholesterolemia (HeFH). Objective To evaluate the efficacy
and safety of JS002 150 mg (Q2W) and 450 mg (Q4W) subcutaneous injection (SC).